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Methods: A retrospective analysis of medical records of three consecutive cohorts of women. 
All cohorts received a digoxin feticide injection on Day 1. Two cohorts were treated with 
laminaria, cohort A of 151 women over 1–2 days and cohort B of 52 women over 1–3 days, 
and cohort C of 151 women was treated with Dilapan-S over 1–3 days.
Results: Adequate cervical priming for dilatation and evacuation (D&E) on Day 2 was 
achieved in 98% of the Dilapan-S cohort and 56% of cohort A and 40% of the cohort B lami-
naria cohorts. Return to theater for D&E 3–4 hours after dilator insertion on Day 2 occurred 
in 62.3% of Dilapan-S cohort C and 9.3% of cohort A and 4% of cohort B laminaria cohorts 
(P = 0.001). A mean D&E theater time of 19 minutes for laminaria cohort A was reduced by 
10.1% in the Dilapan-S cohort C (P = 0.02). The incidence of unscheduled overnight delivery 
outside the clinic was 0% for Dilapan-S and 1.3% for cohort A and 3.8% for cohort B lami-
naria cohorts (P = 0.14).
Conclusion: Dilapan-S osmotic dilators are superior to laminaria in producing more cervical 
priming and dilatation in a shorter time. This enables 17–22 week D&E procedures to be carried 
out in fewer days and in shorter theater times. They also eliminate the risk of an unscheduled 
overnight delivery outside the clinic.
Keywords: late second-trimester surgical abortion, dilatation and evacuation, cervical priming, 
osmotic dilators, Dilapan-S, laminaria tents
Introduction
The Pregnancy Advisory Centre is a government-funded day surgery clinic providing 
over 2500 surgical and medical terminations of pregnancy each year in South Australia, 
Australia. Second-trimester surgical termination by dilatation and evacuation (D&E) 
of pregnancies up to 22 weeks’ gestation has been performed in this clinic using miso-
prostol and osmotic cervical dilators for cervical priming since 1994. Misoprostol alone 
has been used at 13–16 weeks’ gestation, and misoprostol as an adjunct to osmotic 
dilators at 17–22 weeks’ gestation. The incidence of these terminations has remained 
fairly constant over this period with approximately 9% of all terminations occurring 
at 13–16 weeks’ gestation and 4% at 17–22 weeks’ gestation, figures much in line 
with published figures overseas.1 At 13–16 weeks, women can be safely terminated 
in a 1-day D&E procedure with misoprostol alone for cervical priming.2 Although 
many women at 17–18 weeks can be terminated in 1 day, an increasing proportion 
of later gestations cannot be adequately cervically dilated for a safe D&E procedure 
in 1 day.3 Therefore, in the Pregnancy Advisory Centre clinic, all 17–22 weeks’ ges-
tation women are treated as potentially multiday procedures with a combination of International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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misoprostol and osmotic cervical dilators. Over the first 10 
years of this clinic, increasing experience allowed the dosage 
and timing of the misoprostol to be gradually developed to 
the regimen that is now used.
The routine use of digoxin feticide began in 2004 because 
a macerated fetus is more easily evacuated at D&E.4 It was 
determined that the majority of women prefer the reassur-
ance that the fetus will not be alive at D&E and that should 
an unscheduled precipitate delivery occur at home the fetus 
will not be born alive. For the first 5 years the digoxin was 
administered on Day 1 without anesthesia. In July 2009, as 
some women found this procedure distressing, anesthesia on 
Day 1 was introduced as a routine, the digoxin being injected 
into the fetal body under ultrasound guidance. At the same 
time, advantage was taken of the opportunity to commence 
the insertion of one or two laminaria tent osmotic cervical 
dilators. After 52 cases it became apparent that this new 
regimen had not resulted in any reduction in the number of 
days’ preparation required before D&E. In February 2010 the 
synthetic osmotic dilator Dilapan-S™ (Fema   International 
Dilapan Distributors: regional offices listed on www.dila-
pan.com) was substituted for laminaria to test for possible 
advantages over laminaria.
With the permission of the Therapeutic Goods Adminis-
tration, the addition of mifepristone 200 mg to misoprostol 
and laminaria was trialled between the two laminaria cohorts 
to enhance cervical dilatation, but after 21 cases the mifepri-
stone was ceased due to a 19% incidence of cervical lacera-
tions and one overnight delivery at home. After the use of 
Dilapan-S in 151 late second-trimester women we decided 
to audit our results, and this number decided the size of the 
major cohorts. We have been unable to find any published 
trials comparing Dilapan-S with laminaria. Because of this 
lack of published data comparing Dilapan-S and laminaria 
for late second-trimester terminations, we decided to research 
the outcomes in our clinic of comparable procedures using 
the two types of osmotic cervical dilators, to determine what 
clinical benefits Dilapan-S might offer.
Materials and methods
The study design was a retrospective review of the clinical 
records of three cohorts of consecutive cases of women 
undergoing surgical termination of pregnancy at 17–22 
weeks’ gestation. Cohort A was of 151 women who on Day 1 
underwent digoxin feticide injection without anesthesia. On 
Day 2, three doses of two misoprostol 200 µg tablets were 
administered sublingually 30 minutes apart. Three hours 
after the last dose, under intravenous propofol anesthesia, 
the cervix was dilated with rigid Hawkin-Ambler dilators to 
a dilatation equal to the weeks of gestation in millimeters less 
2 mm, as in Table 1. This minimum dilatation requirement 
before the insertion of osmotic dilators has been determined 
from experience over the 17 years that we have used this 
regimen in our clinic, and its purpose is to ensure adequate 
subsequent cervical priming for safe D&E the same or next 
day. The dilatation was followed by artificial rupture of the 
membranes, drainage of the liquor, and the insertion of 8 mm 
laminaria tents, the number equalling the weeks of gestation 
minus 11. If no rigid dilatation was needed, the misoprostol 
alone having produced the target dilatation, the woman 
was considered safe for return to theater the same day for 
D&E. Therefore, at the end of the procedure, two moistened 
misoprostol 200 µg tablets were inserted rectally, this route 
ensuring a rapid response. On return to the recovery ward, 
one misoprostol 200 µg tablet was administered sublingually 
every 30 minutes for four doses. D&E was then performed 
2–3 hours later under intravenous propofol anesthesia after 
ensuring that the dilatation of the cervix achieved was 
appropriate for the gestation as detailed in Table 1, again 
a safe minimum determined from 17 years’ experience in 
our clinic. Women with inadequate cervical priming by 
the initial misoprostol were precluded from returning for 
D&E on Day 2 and returned the next morning. On Day 3, 
three doses of two misoprostol 200 µg tablets were again 
administered sublingually 30 minutes apart. Three hours 
after the last dose, D&E was performed under intravenous 
propofol anesthesia.
Cohort B was of 52 women who on Day 1 underwent 
digoxin feticide injection under propofol anesthesia, followed 
by the insertion into the cervical canal of one or two laminaria 
tents. On Day 2, misoprostol 200 µg tablets were administered, 
two sublingually for three doses at half-hour intervals. Half 
an hour to 1 hour after the last dose the woman was taken 
to theater for D&E if the cervix was sufficiently dilated as 
detailed in Table 1, and further laminaria if not. If dilatation 
was inadequate, the membranes were ruptured and the liquor 
drained before further laminaria were inserted.   Subsequent 
Table 1 Minimum millimeter (mm) cervical dilatation required at 
each gestation before osmotic dilator insertion on the morning of 
Day 2 and before dilatation and evacuation (D&e) procedure
Gestation in weeks 17 18 19 20 21 22
Cervical dilatation in mm  
before osmotic dilator  
insertion on Day 2
15 16 17 18 19 20
Cervical dilatation in mm  
before D&e operation
18 20 22 24 26 28International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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treatment was the same as in the 151 laminaria cohort described 
  previously. After 52 cases, concern was raised that the number 
of women needing a 3-day procedure had actually risen rather 
than fallen, and Dilapan-S was then substituted for laminaria 
to determine whether this would reduce the number of women 
needing to return on the third day.
In cohort C, 151 women had 4 mm × 65 mm Dilapan-S 
instead of laminaria. As in cohort B, Day 1 consisted of a 
digoxin feticide injection and the insertion of osmotic dila-
tors under propofol anesthesia, one Dilapan-S dilator being 
inserted at 17–19 weeks’ gestation and two dilators at 20–22 
weeks’ gestation. On Day 2, misoprostol 200 µg tablets were 
administered, two sublingually for three doses at half-hour 
intervals, and the woman was taken to theater 1/2–1 hour 
after the last dose for D&E if the cervix was sufficiently 
dilated as detailed in Table 1, and further osmotic dilators if 
not. If further osmotic dilatation was required, after rupturing 
the membranes and draining the liquor, Dilapan-S dilators 
were inserted, two or three at 17–19 weeks and four or five 
at 20–22 weeks, under propofol anesthesia, followed by the 
same misoprostol routine as in the laminaria cohorts when 
return to theater for D&E the same day was planned. Three 
hours after the last dose of misoprostol, the woman was 
returned to theater for D&E. All D&E procedures at our 
clinic are performed under intravenous propofol anesthesia 
with the addition of an intracervical block of lignocaine local 
anesthetic with adrenaline. Routine intraoperative ultrasound 
guidance is used, allowing the operator to see instruments in 
the uterus and direct them to the fetal parts safely.
Medical records were examined and data were collected 
relating to parity, gestation, the number of procedures, the 
number of days of treatment, the D&E theater time for each 
woman in each cohort, and any complications. The theater 
times were used rather than operation times, as these were 
collected with more strict precision, the time of entry into 
and exit from the operating theater being collected and 
recorded separately by both the anesthetist and theater nurse 
with cross-checking. All the procedures analyzed were car-
ried out by operators with many years of experience. The 
demographic make-up of all three cohorts was similar. The 
statistical analysis was performed using Fisher’s exact test.
Results
The number of women in each cohort completing a D&E 
on the morning of Day 2, with a breakdown by parity, is 
shown in Table 2. In this table the number of women in each 
of the laminaria cohorts was reduced by 2 because of two 
unscheduled out-of-clinic deliveries overnight in each of 
the laminaria cohorts. There were no unscheduled deliveries 
outside the clinic for Dilapan-S, and two deliveries for each 
of the laminaria cohorts, an incidence of 1.3% for cohort A 
and 3.8% for cohort B (P = 0.14).
The number of women in each cohort completing a D&E 
on the morning of Day 2 was 70 of 149 (47%) in laminaria 
cohort A, 54 of 151 (36%) in the Dilapan-S cohort C, and 18 
of 50 (36%) in laminaria cohort B. The number of women in 
each cohort completing a D&E after 2 days was 148 of 151 
(98%) in Dilapan-S cohort C, 84 of 149 (56%) in laminaria 
cohort A, and 20 of 50 (40%) in laminaria cohort B. The 
advantage of the Dilapan-S cohort over the two laminaria 
cohorts was 43% and 59%, respectively.
Return to theater for same-day D&E 3–4 hours after 
dilator insertion on Day 2 occurred in 94 of 151 (62.3%) in 
Dilapan-S cohort C, 14 of 151 (9.3%) in laminaria cohort A, 
and two of 52 (3.8%) in laminaria cohort B, a highly signifi-
cant Dilapan-S advantage (P = 0.001).
The mean D&E theater times for each cohort are also 
shown in Table 2. The overall mean D&E theater time for 
the three cohorts was 17.1 minutes with Dilapan-S cohort C, 
19.0 minutes with laminaria cohort A, and 18.0 minutes 
with laminaria cohort B. The D&E theater time reduction 
advantage of Dilapan-S was 10.1% over laminaria cohort A 
and 5.1% over laminaria cohort B (P = 0.02).
As well as the two home deliveries in each of the lami-
naria cohorts, other complications were cervical lacerations 
requiring suture in 3.4% (two women) of laminaria cohort A, 
5.8% (three women) of cohort B, and 1.3% (two women) of 
Dilapan-S cohort C, and blood loss over 500 mL in 1.9% 
(one woman) of laminaria cohort B and no women in the 
other two cohorts. There were no perforations, infections, 
retained products, anesthetic problems, or hospital admis-
sions in any of the cohorts.
The trial of mifepristone in 21 women between the lami-
naria cohorts resulted in one unscheduled delivery outside 
the clinic, a 4.8% incidence, and four cervical lacerations, 
a 19% incidence.
Discussion
From 17 weeks’ gestation, an increasing number of women 
cannot be safely terminated by D&E in 1 day, misoprostol 
priming alone becoming progressively inadequate in providing 
a safe degree of cervical softening and dilatation. A previous 
study by our clinic determined that inadequate cervical priming 
increased the risk of perforation of the uterus during late-gesta-
tion D&E.3 These gestations therefore require the use of osmotic 
dilators as an adjunct to misoprostol. We have compared the International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
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outcomes in three cohorts of women of two laminaria regimens 
and one Dilapan-S regimen of osmotic dilators. In all cohorts on 
Day 1 an intrafetal injection of digoxin 1.0 mg was performed 
to produce fetal demise and maceration.4,5 The demographics 
of the women were similar in all cohorts.
A Cochrane review in 2010 concluded that cervical 
preparation with osmotic dilators and misoprostol before 
second-trimester D&E is safe and effective.6 Dilapan-S 
(Figure 1) is a hydrophilic polymer rod manufactured from 
Aquacryl, a proprietary hydrogel, which is hygroscopic and 
expands radially more rapidly, consistently, and to a greater 
degree than laminaria tents, which are a natural product 
manufactured from dried seaweed stems (Figure 2). There-
fore, fewer Dilapan-S can be inserted for shorter periods 
of time. Most dilatation occurs within 4–6 hours, and one 
4 mm Dilapan-S produces 7.8–10 mm dilatation at 2 hours 
and 12.7–14.6 mm after 24 hours. The radial pressure on the 
cervix of the expanding Dilapan-S also provides cervical 
ripening via prostaglandin synthesis.2
The main finding of our retrospective study was that the 
aforementioned characteristics of Dilapan-S enabled us to 
markedly reduce the number of women who needed to return 
on Day 3 for D&E. With Dilapan-S, 98% of women under-
went D&E on Day 2 as opposed to 56% in laminaria cohort 
A and 40% in laminaria cohort B, the laminaria cohort with 
the same regimen as the Dilapan-S cohort, an improvement 
of 1.75-fold and 2.45-fold, respectively.
The number of women ready for D&E on the morning 
of Day 2 was 47% for laminaria cohort A and 36% each for 
laminaria cohort B and the Dilapan-S cohort C. The percentage 
was higher for laminaria cohort A because these women went 
to theater 3 hours after the last dose of misoprostol, as opposed 
to the interval being 1/2–1 hour in the other two cohorts. The 
shorter interval was necessary to allow time for the same-
day return to theater for D&E for women with inadequate 
cervical priming in the morning. Return to theater for D&E 
3–4 hours after dilator insertion on Day 2 occurred in 62.3% of 
Dilapan-S cohort C, 9.3% of laminaria cohort A, and 3.8% of 
laminaria cohort B, a highly significant Dilapan-S advantage 
(P , 0.001). The superiority of the Dilapan-S was due to its 
greater and more rapid priming of the cervix, enabling return 
to theater in the early afternoon of the same day for D&E after 
insertion of the osmotic dilators in the morning.
Another significant advantage of Dilapan-S was that 
it eliminated the risk of unscheduled overnight delivery at 
home, there being none with Dilapan-S and two cases in each 
of the laminaria cohorts, an incidence of 0% in the Dilapan-S 
cohort, 3.8% in laminaria cohort A, and 1.3% in laminaria 
cohort B. As our day surgery clinic is staffed only in office 
hours, it is unable to treat a woman with an unscheduled 
delivery out of hours. Such a delivery can be very distressing 
for a woman and is to be avoided if possible.
A mean D&E theater time of 19 minutes for laminaria 
cohort A was reduced by 10.1% in Dilapan-S cohort C and 
by 5.1% in laminaria cohort B, the Dilapan-S appreciably 
reducing the theater times due to greater cervical priming 
(P = 0.02). Cervical lacerations needing suture were 1.3% 
Table 2 Proportion of women undergoing dilatation and evacuation (D&e) on the morning of Day 2 and mean theater time in each of 
two laminaria tent cohorts and one Dilapan-s cohort by parity
Cohort Nulliparous women Parous women
Cohort A  
151 women  
laminaria
Cohort B  
52 women  
laminaria
Cohort C  
151 women  
Dilapan-S
Cohort A  
151 women  
laminaria
Cohort B  
52 women  
laminaria
Cohort C  
151 women  
Dilapan-S
D&e morning  
Day 2
30 of 78 (38%) 10 of 34 (29%) 27 of 80 (34%) 40 of 71 (56%) 8 of 16 (50%) 27 of 71 (38%)
Mean D&e  
theater time
19.2 mins (n = 78) 17.6 mins (n = 34) 16.6 mins (n = 80) 19.0 mins (n = 71) 17.4 mins (n = 16) 17.0 mins (n = 71)
Figure 1 Dilapan-s before and after hydration.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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with Dilapan-S cohort C, 3.4% in laminaria cohort A, and 
6% in laminaria cohort B, again demonstrating the benefit of 
the greater cervical priming produced by Dilapan-S. There 
were no serious complications in any cohort. These rates 
compare favorably with Chasen et al,7 who reported a late 
second-trimester D&E complication rate of 5%. No uterine 
perforations occurred in the cohorts we studied, which we 
attribute to our serial use of osmotic dilators. Uterine perfo-
ration is a serious complication of second-trimester surgical 
abortion with a reported incidence of 0.2%–0.4%.2,3
Hayes and Fox8 have reported that Dilapan-S can be dif-
ficult to remove due to entrapment and fragmentation. This 
problem was not met in the Dilapan-S cohort we studied, 
which we attribute to our use of the dilators being in graded 
serial stages over 2 days along with the adjuvant use of 
high-dosage misoprostol. The misoprostol dosage we have 
found to be optimally effective is approximately twice that 
recommended in most published studies. Despite this higher 
dosage and 20%–25% of our parous women having a cesarean 
scar, we have never seen a uterine rupture in 17 years of this 
usage. We attribute this to never exceeding 400 µg per dose of 
misoprostol, with a minimum interval of 30 minutes between 
doses, and avoiding the vaginal route of administration. 
Wilson et al9 have compared Lamicel osmotic dilators with 
misoprostol plus Dilapan-S and shown that although both 
regimens allowed completion in 1 day for up to 18 weeks’ 
gestation, the former had two cases of hemorrhage requiring 
hospitalization compared with no serious complications in 
the misoprostol plus Dilapan-S group.
Our brief trial of mifepristone in 21 women led to one 
unscheduled out-of-clinic delivery, a 4.8% incidence, and 
excessive softening of the cervix with four cervical lacera-
tions, a 19% incidence of cervical injury. Carbonell et al10 have 
reported that administering mifepristone as an adjunct to miso-
prostol used for cervical priming before D&E in 12–20 week 
second-trimester abortions makes surgery easier and shorter 
but with the drawbacks of increased cost, more patient clinic 
visits, and the expulsion of the fetus before D&E being a risk 
with mifepristone. They pointed out that this has consequences 
for the woman’s health, as this expulsion may occur at any 
time and place. The Cochrane review has also concluded that 
mifepristone is associated with high rates of preprocedural 
Figure 2 Laminaria tents before and after hydration.International Journal of Women’s Health
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expulsions and does not appear to be a useful method of 
  cervical preparation before second-trimester D&E.6
Surgical termination of a second-trimester pregnancy has 
fewer complications, is completed in a shorter time, makes 
less demand on clinic staff time, and has a lower cost than 
medical termination.11 A significant proportion of women 
with fetal anomalies or fetal death are treated in hospital by 
labor induction. Bryant et al12 state that women facing this 
situation should be offered a choice of methods, as D&E is 
significantly safer and more effective than labor induction for 
second-trimester abortion for fetal indications. The surgical 
option can be made even more efficient by determining the 
optimal method of cervical priming. Our study has shown 
that a regimen combining misoprostol and Dilapan-S osmotic 
dilators is a move toward this optimum. Our study shows 
the benefit of misoprostol, when acting over a few hours, as 
an adjunct to osmotic dilators. In laminaria cohort A, where 
D&E was performed 3 hours after the last dose of miso-
prostol, 56% of parous women were primed for operation, 
compared with only 38% of the Dilapan-S cohort where D&E 
was 1/2–1 hour after the last dose of misoprostol.
A limitation of our study is that the large laminaria cohort A 
did not have exactly the same regimen as Dilapan-S, and 
laminaria cohort B, which exactly matched the regimen of 
the Dilapan-S cohort C, was only 52 women in size due to its 
early abandonment because of its failure to improve on any of 
the measures of outcome of the preceding laminaria cohort A. 
Nevertheless, the advantages of Dilapan-S were still great 
enough to achieve statistical significance. Another limitation 
of our study is that it was retrospective. The use of theater 
times rather than operation times was therefore unavoidable 
because with the study being retrospective, operation times had 
not been recorded with the same precision that would occur in 
a prospective study. Fortunately, our clinic has a protocol in 
place for precision in the recording of theater times.
This study showed that Dilapan-S osmotic dilators are 
superior to laminaria in producing more cervical priming and 
dilatation in a shorter time. This enables 17–22 week D&E 
procedures to be carried out in fewer days and in shorter 
theater times. It also eliminates the risk of an unscheduled 
overnight delivery outside the clinic. The higher cost of 
Dilapan-S over laminaria tents is offset by the fewer number 
of dilators required to produce the same dilatation and the 
shorter duration of treatment required.
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